BIRC5 and cancer: Moreover, new platforms such as the survivin-targeted vaccine OVM-200 and Maveropepimut-S (MVP-S), which activate specific anti-cancer T-cell responses independent of the presence of platinum sensitivity, are also being investigated in clinical trials [83].